A field note should let another person understand exactly what was observed. In this case the documented offer is Hims 3-in-1 Hard Mints, meaning the 3-in-1 chew listing sildenafil, tadalafil and vitamin B12. The review keeps product identity, advertised terms and open questions in separate entries. It is a record of public information, not a report from a patient visit.
Availability: Public product listing; individual eligibility and current prescription require confirmation.
The exact product
The distinguishing observation is two ED drugs plus a vitamin, rather than three ED drugs. Record the full active list and supplied form before summarizing the product as a pill, chew or ED treatment. Those short categories lose information that may matter to a pharmacist. A later prescription can differ from the listing, so keep the advertised record and the dispensed label identifiable. Neither should silently replace the other in a treatment history.
| Provider | Hims |
|---|---|
| Listed active ingredients | Sildenafil + tadalafil + vitamin B12 |
| Dosage form | Compounded mint-flavored chew |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | Hims: current ED treatment catalog · Hims: Hard Mints formulation safety library · Hims: Hard Mints chewable ED medicines |
Price, supply and payment
The price observation is From $30/month in the ED catalog. Attach a quantity and billing period only where the source provides them together. Keep any calculated monthly equivalent separate from the actual payment schedule. If the figure is approximate, a starting price or unmatched to a complete plan, preserve that qualifier. A useful financial note shows the limit of the observation instead of making the blank fields look complete.
| Current catalog headline | From $30/month |
|---|---|
| Separate chewable-page offer | Selected sildenafil/tadalafil mints from $6/use |
| Price limitation | The two headlines do not establish a five-chew plan |
| Name limitation | Other Hard Mints formulations have different active ingredients |
What the research can support
The evidence entry reads: ingredient and regimen research; Hims user surveys are not trials of this exact chew. The unanswered part is the matching quantity, strengths and upfront payment. Record the studied population, preparation and outcome before linking research to a commercial product. An abstract can establish what its authors reported while leaving methods unavailable for full appraisal. A provider's own survey belongs in a different category from a randomized comparison; a field note should make that source difference easy to see.
| Evidence boundary | ingredient and regimen research; Hims user surveys are not trials of this exact chew |
|---|---|
| Not established here | the matching quantity, strengths and upfront payment |
| Clinical and regulatory references | Cui et al. (2015): daily tadalafil with as-needed sildenafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil · MedlinePlus: Tadalafil |
Safety questions for the prescriber
Use the medication list as a reconciliation document. It should include nitrate or nitrite use, riociguat, other ED treatments, blood-pressure drugs and relevant medical conditions. Do not mark Hims 3-in-1 Hard Mints as cleared merely because a prior ED drug was tolerated. The clinician must consider the actual formula and history. Record the instructions received rather than deriving a dose, overlap or switching interval from this review.
| Multiple PDE5 inhibitors | Standard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed. |
|---|---|
| Added nutrients | Review actual amounts and duplicate supplements; nutrient inclusion does not prove improved ED efficacy. |
Availability and the actual prescription
The access observation is time-specific: Public product listing; individual eligibility and current prescription require confirmation. Distinguish a public catalog entry, a safety-library entry, an account offer and a clinician-approved prescription. They are four different states. If support supplies a clarification, save the date and exact product name. A link that opens successfully proves only that a page is reachable, not that enrollment or dispensing has been verified.
Refills, changes and cancellation
When the plan changes, create a new entry rather than overwriting the old one. Note who advised the change, which prescription it concerns and what happens to the next order. A useful question to carry forward is “Why does this prescription combine both PDE5 inhibitors, and what role does B12 serve?” Keep clinical response notes separate from shipment and payment confirmations. This makes it easier to identify an unresolved handoff before a refill proceeds on outdated assumptions.
| Next charge | The next order date is the charge/processing date; a first refill can be scheduled early. |
|---|---|
| Cancellation notice | At least 48 hours before the next order, according to support guidance. |
| Already processing | Ending a subscription does not cancel an order already processing or shipped. |
| Refund boundary | No refund guaranteed after pharmacy processing. |
| Policy sources | Hims Support: canceling a subscription · Hims Support: refund policy · Hims Support: when billing occurs |
Compare named products
The related reviews serve as cross-references, not endorsements. Compare a named field such as active list, dosage form or payment term and state why the difference matters. Do not infer a matching strength from a similar product name. If a proposed alternative has an unverified current plan, retain that uncertainty in the comparison instead of treating the alternative as immediately obtainable.
Questions to keep with the offer
The final field is the boundary of the investigation. We read the cited documents but did not order Hims 3-in-1 Hard Mints, inspect a pharmacy, test support or observe clinical outcomes. That boundary belongs in the record as much as the ingredients do. New account or prescribing information can update the practical decision; it does not retroactively turn this public-document review into a firsthand assessment.
| Ask about this formula | Why does this prescription combine both PDE5 inhibitors, and what role does B12 serve? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Back to all individual product reviews
Trace the information
Checked October 7, 2026. Provider pages establish advertised claims. Medical sources supply general context; citation does not imply endorsement.
- Hims: current ED treatment catalogProvider catalog; individual named offers and starting prices
- Hims: Hard Mints formulation safety libraryProvider formulation document; includes options not confirmed in the main catalog
- Hims Support: canceling a subscriptionProvider policy; 48-hour notice and orders already processing
- Hims Support: refund policyProvider policy; no guaranteed refund after pharmacy processing
- Hims Support: when billing occursProvider policy; next order date, charge timing, and subscription intervals
- Hims Support: changing the next order dateProvider support; refill rescheduling differs from cancellation
- Cui et al. (2015): daily tadalafil with as-needed sildenafilPrimary clinical study; 180 patients, specific regimen, abstract reviewed via NCBI
- Hims: Hard Mints chewable ED medicinesProvider source; compounded formulations and advertised starting prices
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications
- MedlinePlus: SildenafilDrug information; standard sildenafil products
- MedlinePlus: TadalafilDrug information; standard tadalafil products